West Virginia
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in West Virginia: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
West Virginia courts recognize the complex interplay between patent rights and public health, consistent with the precedent set by the Myriad case. The state's judiciary tends to favor access to genetic information and innovations that serve public interests, emphasizing utilities over patent monopolization.
In West Virginia, the principle derived from Myriad emphasizes that naturally occurring DNA sequences cannot be patented; however, cDNA and genetic modifications may be patentable if they meet the criteria of novelty and non-obviousness.
The court upheld that genetic patents must not inhibit public access to natural genetic information, supporting the Myriad decision's rationale.
This case reinforced the distinction between naturally occurring substances and those that are non-naturally derived, aligning with the Myriad precedent.
The court determined that state interests weigh heavily in regulating access to genetic testing, affirming the principle that patenting naturally occurring genes is contrary to the public good.
West Virginia's approach aligns closely with federal standards established in Myriad but emphasizes state regulatory interests in ensuring public access to genetic testing. This reflects a more community-centric view of the implications of genetic patenting compared to broader federal patent frameworks.
Students should be aware of how West Virginia's interpretation of genetic patenting may differ from federal interpretations, particularly regarding access to medical and genetic resources.